Beam Therapeutics (BEAM) Price & Analysis

Compare

1,912 Followers

BEAM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$13.53 - $35.25

Previous CloseN/A

Volume491.48K

Average Volume (3M)2.90M

Market Cap

$2.39B

Enterprise Value$739.40M

Total Cash (Recent Filing)$1.15B

Total Debt (Recent Filing)$154.80M

Price to Earnings (P/E)―

Beta2.40

Next Earnings

Nov 10, 2025

EPS Estimate

-1.05

Last Dividend Ex-Date

Feb 04, 2014

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.00

Shares Outstanding101,162,025

10 Day Avg. Volume2,809,227

30 Day Avg. Volume2,902,750

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.31

Enterprise Value/Revenue12.27

Enterprise Value/Gross Profit332.62

Enterprise Value/Ebitda-1.86

Forecast

1Y Price Target

$40.63

Price Target Upside75.96% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Competitive AdvantageThe potential for a one-time treatment with BEAM-302 may offer a competitive edge vs. multidose options.

Genetic Medicines PortfolioMultiple near-term catalysts position the company to deliver on its vision of developing a portfolio of potentially transformative, one-time genetic medicines.

Sickle Cell FranchiseThe sickle cell franchise remains a cornerstone, with BEAM-101 advancing toward a potential BLA filing and ESCAPE designed to broaden access.

Bears Say

Clinical Differentiation ChallengesManagement believes that increasing total AAT levels above 12.4uM may not provide meaningful clinical benefit, which limits potential differentiation from competitors.

Investor ConcernsInvestor inbounds remain focused on absolute AAT/M-AAT levels – where BEAM-302 is positioned to deliver best-in-class results.

Beam Therapeutics News

Private Markets: Dyna Robotics raises $120M from Nvidia, Amazon

The startup working to develop cost-effective, general-purpose robots announced it has raised $120M in a new funding round,...

9d ago

Cathie Wood Invests $37M into Biotech Stocks, Trims Stake in KTOS, TEM, and ROKU Stocks

Ace hedge fund manager Cathie Wood’s ARK Invest ETFs (exchange-traded funds) reported several notable trades for Wednesday, September 17, 2025, highlighting...

10d ago

TEM

ARCT

Cathie Wood’s ARK Investment buys 491K shares of Beam Therapeutics today

20:56 EDT Cathie Wood’s ARK Investment buys 491K shares of Beam Therapeutics (BEAM) today Published first on TheFly...

10d ago

BEAM

Cathie Wood Bets on AMD, Bullish, and Figma; Trims Tempus AI, Roku

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) reported several notable trades on Tuesday, September 16, 2025, according to daily disclosures....

11d ago

AMD

FIG

Beam competitive position intact after Wave data, says Clear Street

Clear Street says Beam Therapeutics (BEAM) is rallying after Wave Life Sciences (WVE) reported a data update from...

24d ago

WVE

BEAM

Wall Street Sees Massive Growth Potential in These 3 Russell 2000 Stocks

Small-cap stocks often fly under the radar, but some are now drawing attention from Wall Street. Analysts have...

25d ago

APGE

BEAM

Beam Therapeutics: Strong Buy Rating Backed by Advancements in Genetic Medicine Programs

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Beam Therapeutics, retaining the price target of...

13d ago

BEAM

Strategic Positioning and Technological Advancements Drive Buy Rating for Beam Therapeutics

In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on Beam Therapeutics, with...

18d ago

BEAM

Cathie Wood ‘Buys the Dip’ in Robinhood, CRISPR, and Beam Therapeutics Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made significant multi-million-dollar trades in the fintech and biotech sectors on Tuesday, August 19,...

1M ago

TXG

WGS

Cathie Wood’s ARK Investment buys 509.6K shares of Beam Therapeutics today

20:06 EDT Cathie Wood’s ARK Investment buys 509.6K shares of Beam Therapeutics (BEAM) today Published first on TheFly...

1M ago

BEAM

Cathie Wood Pours Over $46M into Biotech Stocks, 8/19/2025

1M ago

WGS

BEAM

Cathie Wood’s ARK Investment buys 395K shares of Beam Therapeutics today

20:21 EDT Cathie Wood’s ARK Investment buys 395K shares of Beam Therapeutics (BEAM) today Published first on TheFly...

1M ago

BEAM

Beam Therapeutics announces U.S. FDA granted RMAT to BEAM-101

Beam Therapeutics (BEAM) announced that the United States Food and Drug Administration, FDA, has granted Regenerative Medicine Advanced...

1M ago

BEAM

3 Small-Cap Stocks That Could Double Your Money, According to Analysts

Small-cap stocks often fly under the radar, but some are now drawing attention from Wall Street. Analysts have...

2M ago

AIOT

BEAM

BEAM FAQ

What was Beam Therapeutics’s price range in the past 12 months?

Beam Therapeutics lowest stock price was $13.53 and its highest was $35.25 in the past 12 months.

What is Beam Therapeutics’s market cap?

Beam Therapeutics’s market cap is $2.39B.

When is Beam Therapeutics’s upcoming earnings report date?

Beam Therapeutics’s upcoming earnings report date is Nov 10, 2025 which is in 43 days.

How were Beam Therapeutics’s earnings last quarter?

Beam Therapeutics released its earnings results on Aug 05, 2025. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.113 by $0.113.

Is Beam Therapeutics overvalued?

According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Beam Therapeutics pay dividends?

Beam Therapeutics pays a Quarterly dividend of $0.225 which represents an annual dividend yield of N/A. See more information on Beam Therapeutics dividends here

What is Beam Therapeutics’s EPS estimate?

Beam Therapeutics’s EPS estimate is -1.05.

How many shares outstanding does Beam Therapeutics have?

Beam Therapeutics has 101,162,025 shares outstanding.

What happened to Beam Therapeutics’s price movement after its last earnings report?

Beam Therapeutics reported an EPS of -$1 in its last earnings report, beating expectations of -$1.113. Following the earnings report the stock price went down -2.197%.

Which hedge fund is a major shareholder of Beam Therapeutics?

Currently, no hedge funds are holding shares in BEAM

Beam Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-41.94%

Trailing 12-Months

Asset Growth

10.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Beam Therapeutics

Beam Therapeutics is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. The company operates in the biotechnology sector, targeting genetic diseases through innovative therapies that aim to correct genetic mutations at the single-base level. Beam's core products include various pipeline candidates designed to treat conditions such as sickle cell disease, beta-thalassemia, and other genetic disorders, leveraging its advanced editing capabilities to provide potentially curative options.

Beam Therapeutics (BEAM) Earnings & Revenues

Historic Earnings Reports

BEAM Stock 12 Month Forecast

Average Price Target

$40.63

▲(75.96% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","48":"$48","81":"$81","31.5":"$31.5","64.5":"$64.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,31.5,48,64.5,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.31,21.209230769230768,26.108461538461537,31.007692307692306,35.90692307692308,40.80615384615385,45.70538461538462,50.604615384615386,55.503846153846155,60.403076923076924,65.30230769230769,70.20153846153846,75.10076923076923,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.31,18.18076923076923,20.05153846153846,21.92230769230769,23.793076923076924,25.66384615384615,27.534615384615385,29.405384615384616,31.276153846153846,33.14692307692307,35.01769230769231,36.88846153846154,38.75923076923077,{"y":40.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.31,16.59384615384615,16.877692307692307,17.16153846153846,17.445384615384615,17.729230769230767,18.013076923076923,18.296923076923076,18.58076923076923,18.864615384615384,19.14846153846154,19.432307692307692,19.716153846153848,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.41,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.34,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.83,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.19,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.31,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >